<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621851</url>
  </required_header>
  <id_info>
    <org_study_id>TFR-PRO</org_study_id>
    <nct_id>NCT04621851</nct_id>
  </id_info>
  <brief_title>Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation</brief_title>
  <official_title>Retro-prospective Observational Study on Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR - PRO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety profile of TKI discontinuation in&#xD;
      clinical practice, with particular regard on the risk of progression after treatment&#xD;
      discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 3000 CP-CML patients that must have a history of at&#xD;
      least 4 years of TKI treatment and at least 18 months of DMR. Events developing in patients&#xD;
      after the end of discontinuation and TKI resumption will be considered as linked to the&#xD;
      discontinuation if they will develop within 36 months from the end of discontinuation. This&#xD;
      rule will apply also to subsequent TD attempts. In case of a second or subsequent&#xD;
      discontinuation attempt after the failure of a previous one (for molecular relapse), patients&#xD;
      must have re-achieved a DMR with TKI therapy resumption and must keep DMR for at least 18&#xD;
      months before another TD.&#xD;
&#xD;
      Collection of data will be retrospective and prospective, as each center will collect the&#xD;
      data for 24 months. Patients who discontinued before the opening of this study will&#xD;
      contribute to the retrospective cohort, while those who will discontinue after it will&#xD;
      contribute to the prospective cohort. Patients who discontinued before the opening of this&#xD;
      study but will continue their discontinuation after it, will contribute to both cohorts. For&#xD;
      patients prospectively recruited, monitoring of disease status will be performed to assess&#xD;
      the maintenance of the molecular remission during the study period.&#xD;
&#xD;
      Patients with an atypical BCR-ABL1 fusion gene, which does not allow the use of Q-RT-PCR,&#xD;
      will be monitored by qualitative PCR and will be analyzed separately. For these patients,&#xD;
      negativity of nested qualitative RT-PCR will be considered a surrogate of DMR of patients&#xD;
      monitored by Q-RT-PCR, while loss of negativity of first-round qualitative PCR will be&#xD;
      considered a surrogate of loss of MMR (i.e. molecular relapse). Accordingly, for patients&#xD;
      monitored by qualitative PCR, TKI resumption after TD will be provided in case of a new&#xD;
      positivity of first-round PCR.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>The quantification of the risk of progression</measure>
    <time_frame>36 Month</time_frame>
    <description>To quantify the risk of progression to accelerated phase (AP) or blast phase (BP), expressed as time adjusted rate (TAR), after TKI discontinuation in CML patients who undergo a first or subsequent TKI discontinuation attempt</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the time adjusted rate (TAR) of progression from Chronic phase-Chronic Myeloid Leukemia to Accelerated phase (AP) or Blastic phase (BP) by using the percentage of blasts, promyelocytes, basophils or platelet in blood or bone marrow</measure>
    <time_frame>36 Month</time_frame>
    <description>To compare the TAR (time adjusted rate) of progression to AP or BP that is obtained in the target population to that obtained in a similar population of patients with the same characteristics who do not discontinue TKI treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) after TKI discontinuation.</measure>
    <time_frame>36 Month</time_frame>
    <description>PFS will be defined as time between discontinuation and progression to AP or BP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular relapse (loss of MR3 or MMR)</measure>
    <time_frame>36 Month</time_frame>
    <description>Rate of molecular relapse (loss of MR3 or MMR) at 12 and 24 months after TKI discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival (RFS) after TKI discontinuation.</measure>
    <time_frame>36 Month</time_frame>
    <description>Relapse free survival (RFS) after TKI discontinuation. RFS will be defined as time between discontinuation and loss of MMR (i.e. molecular relapse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of relapsed patients who obtain a new deep molecular response (DMR) within 6-12 months of treatment resumption among all patients who restart TKI treatment because of a molecular relapse after TKI discontinuation.</measure>
    <time_frame>36 Month</time_frame>
    <description>The following criteria will be used to define DMR (43):&#xD;
MR4 = either (i) detectable disease with &lt;0.01% BCR-ABL1IS or (ii) undetectable disease in cDNA with &gt;10 000 ABL1 transcripts.&#xD;
MR4.5 = either (i) detectable disease with &lt;0.0032% BCR-ABL1IS or (ii) undetectable disease in cDNA with &gt;32 000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1.&#xD;
MR5 = either (i) detectable disease with &lt;0.001% BCR-ABL1IS or (ii) undetectable disease in cDNA with &gt;100 000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>Patients who discontinued before the opening of this study will contribute to the retrospective cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>Patients who will discontinue after it will contribute to the prospective cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective/Prospective cohort</arm_group_label>
    <description>Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The target population will include all CML patients presently eligible for treatment&#xD;
        discontinuation independently of whether they discontinued or not. For the time they did&#xD;
        not discontinue they will contribute to the reference cohort, while after TD they will&#xD;
        contribute data to the discontinuation cohort. In case of treatment resumption, the patient&#xD;
        will still contribute to the discontinuation cohort for 36 months after treatment&#xD;
        resumption, while he/she will contribute to the reference cohort thereafter, assuming a new&#xD;
        TD did not occur.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated IRB/IEC-approved informed consent for the prospective cohort&#xD;
             patients.&#xD;
&#xD;
          2. Age &gt;= 18 years.&#xD;
&#xD;
          3. Male or female patients with CML diagnosed in chronic phase (CP).&#xD;
&#xD;
          4. At least 4 years of TKI treatment.&#xD;
&#xD;
          5. At least 18 months of DMR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
          -  CML diagnosed in AP or BC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabetta Abruzzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S. Eugenio Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Accurso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.U. Policlinico &quot;Paolo Giaccone&quot; Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Annunziata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot; Napoli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Passamonti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Circolo e Fondazione Macchi Varese, ASST dei Sette Laghi Varese</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Bonifacio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituti Ospitalieri di Verona- Policlinico G.B. Rossi Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Caocci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CTMO - Ospedale &quot;Businco&quot; Cagliari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Lunghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Milano S. Raffaele Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiara Elena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo di Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Crugnola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Az Ospedaliera Universitaria Parma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Galimberti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Pisana Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandra Iurlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano Levato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Az. Ospedaliera Pugliese - Ciaccio (AOPC) Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Cristina Miggiano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda ULSS 8 &quot;Berica&quot; Ospedale San Bortolo Vicenza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrizia Pregno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Città della Salute e della Scienza di Torino S. G.Battista Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davide Rapezzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Cuneo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosaria Sancetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale dell'Angelo Mestre Venezia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabio Stagno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.O. Gaspare Rodolico, Catania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigia Luciano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria-Università degli Studi di Napoli &quot;Federico II&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.S.O. Ordine Mauriziano, P.O. Umberto I Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp leCoutre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University of Berlin · Medical Department, Division of Oncology and Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne Saussele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarit Assouline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Álvarez-Larrán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CARLO GAMBACORTI PASSERINI</last_name>
    <phone>+39 233.9553</phone>
    <email>carlo.gambacorti@unimib.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nora GIELLO</last_name>
    <phone>+39 233 9883</phone>
    <email>noragiello.hsg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McGill University - Jewish General Hospital Division of Hematology and Department of Oncology</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarit Assouline, MD</last_name>
      <phone>001 514 3408207</phone>
      <email>sarit.assouline@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Sarit Assouline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University of Berlin - Clinic of Medicine - Hematology and Oncology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp le Coutre, MD</last_name>
      <phone>+49 30 450553077</phone>
      <email>philipp.lecoutre@charite.de</email>
    </contact>
    <investigator>
      <last_name>Philipp le Coutre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mannheim, Mannheim, Germania</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Saussele</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST-Monza</name>
      <address>
        <city>Monza</city>
        <state>Italy/MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gambacorti-Passerini, MD</last_name>
      <phone>+390392339553</phone>
      <email>carlo.gambacorti@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Gambacorti-Passerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC di Ematologia</name>
      <address>
        <city>Milano</city>
        <state>Italy/Milano</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Iurlo</last_name>
      <phone>+390255033362</phone>
      <email>aiurlo@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Iurlo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Tor Vergata Ospedale S. Eugenio</name>
      <address>
        <city>Rome</city>
        <state>Italy/Rome</state>
        <zip>00142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese</last_name>
      <email>elisabetta.abruzzese@uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; Policlinico S. Orsola Malpighi,</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianantonio Rosti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTMO Ematologia Ospedale &quot;Businco&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Caocci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Catania Cattedra di Ematologia Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Stagno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SOC Ematologia Az. Ospedaliera Pugliese Ciaccio (AOPC)</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano Levato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Cuneo</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davide Rapezzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Ematologia O spedale Milano S. Raffaele</name>
      <address>
        <city>Miano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Lunghi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Annunziata</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Università degli Studi di Napoli &quot;Federico II&quot; Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigia Luciani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Accurso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unità operativa Ematologia e CTMO Az Ospedaliera Universitaria</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Crugnola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Elena</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Pisa Azienda Ospedaliera Pisana Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Galimberti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabella Capodanno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino S. G.Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Pregno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa a Dir. Universitaria Ematologia e Terapie Cellulari A.S.O. Ordine Mauriziano, P.O. U mberto I</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Fava</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese, ASST dei Sette Laghi,</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Passamonti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia Ospedale dell'Angelo Mestre</name>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosaria Sancetta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Verona Div. di Ematologia Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Bonifacio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Ematologia Azienda ULSS 8 &quot;Berica&quot; Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cristina Miggiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Alvarez-Larràn</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>CARLO GAMBACORTI PASSERINI</investigator_full_name>
    <investigator_title>Professor of Hematology University of Milano Bicocca Director, Dept. of Hematology S.Gerardo Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT04621851/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

